High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
The emergence of significant arboviruses and their spillover transmission to humans represent a major threat to global public health. No approved drugs are available for the treatment of significant arboviruses in circulation today. The repurposing of clinically approved drugs is one of the most rap...
Main Authors: | Cuiling Ding, Wanda Tang, Binghui Xia, Haoran Peng, Yan Liu, Jiaqi Wang, Xu Zheng, Yangang Liu, Lanjuan Zhao, Yanhua He, Zhongtian Qi, Hao Ren, Hailin Tang, Ping Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/14/7/1381 |
Similar Items
-
Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01) -
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
by: Carla Rizzo, et al.
Published: (2023-04-01) -
Drugs, Devices, and the FDA: Part 1
by: Gail A. Van Norman, MD
Published: (2016-04-01) -
A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
by: Wanlu Ma, et al.
Published: (2021-02-01) -
Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)